BiotechTube
Home/Pipeline/V2ACT Immunotherapy

V2ACT Immunotherapy

Undisclosed Solid Tumors

Phase 1Active (via JV V2ACT Therapeutics)

Key Facts

Indication
Undisclosed Solid Tumors
Phase
Phase 1
Status
Active (via JV V2ACT Therapeutics)
Company
Genelux

About Genelux

Genelux is a clinical-stage biotech focused on developing oncolytic viral immunotherapies to treat cancer. Its mission is to leverage its proprietary CHOICE™ platform, built on the vaccinia virus backbone, to create therapies that deliver a full complement of tumor neoantigens and stimulate a potent, personalized immune response. The company's strategy centers on advancing its lead candidate, Olvi-Vec, through late-stage trials in ovarian cancer and other solid tumors, while pursuing strategic partnerships and leveraging in-house manufacturing capabilities to build a fully integrated therapeutics company.

View full company profile

Therapeutic Areas

OncologyImmuno-Oncology

Other Undisclosed Solid Tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
ERAS-113ErascaDiscovery
Multiple ProgramsAktis OncologyDiscovery
BAT5506CompugenPreclinical
Precision DACsPrelude TherapeuticsDiscovery
ATOR-4066Alligator Bioscience ABDiscovery/Preclinical
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical
Albumin Shield™-Enabled OVTheriva BiologicsPreclinical